Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Zevra Therapeutics, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics, Inc.

Zevra Therapeutics develops therapies for rare diseases, specifically focusing on unmet patient needs. The company is self-described as pursuing a nimble and data-driven approach to therapeutics.

Metric
Company Name	Zevra Therapeutics, Inc.	Axsome Therapeutics, Inc.
Symbol	ZVRA	AXSM
MSH ID	COM:ZEVRA	COM:AXSOME
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count	65	569
Website	zevra.com	axsome.com
LinkedIn
Founders

Metric
Market Cap	235.22M	3.92B
Enterprise Value
Monthly Web Traffic		7.82K
Web Traffic Growth		-0.74
Valuation
Raised Capital		225M

Metric
Revenue	27.46M	270.60M
Revenue (LTM)
Revenue (NTM)
Gross Profit	24.52M	237.70M
EBITDA	-49.60M	-176.07M
Operating Income	-49.60M	-182.91M
Net Income	-46.05M	-239.24M
EPS	-1.30	-5.27
Diluted EPS	-1.30	-5.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.93	0.90
Operating Profit Margin	-1.56	-0.86
EBITDA Margin	-1.81	-0.65
Net Profit Margin	-1.68	-0.88
Return on Equity	-0.54	-1.12
Return on Assets	-0.27	-0.41
Return on Capital Employed	-0.22	-0.52

COM:ZEVRA

Zevra Therapeutics

Last Close

7.99

14/02 21:00

Market Cap

235.22M

Beta: -

Volume Today

340.99K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-5.05	-20.81
P/B Ratio	2.99	16.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	18.84	16.65
EV Multiple	-3.43	-11.57

Metric
Days Sales Outstanding	1.14K	128.09
Days Payables Outstanding		506.28
Days Inventory Outstanding	660.00	229.29
Operating Cycle	1.14K	383.54
Cash Conversion Cycle	-154.52	-229.81
Asset Turnover	0.19	0.53

Metric
Operating Cash Flow	-33.53M	-145.08M
Free Cash Flow	-33.83M	-145.66M
Cash Flow to Debt	-0.49	-0.81
Operating Cash Flow/Sales	-1.20	-0.54
Free Cash Flow Yield	-0.09	-0.03

Metric
Cash & Equivalents	43.05M	386.19M
Accounts Receivable	-9.08M	-57.12M
Inventory	9.84M	15.13M
Goodwill	4.70M	12.04M
Debt to Capitalization	0.64	0.65
Debt to Assets	0.32	0.31
Current Ratio	6.31	4.46
Quick Ratio	6.23	3.46

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.24	0.24
R&D to Revenue	1.04	0.37
SG&A to Revenue	0.72	0.44